Quantcast

Latest Vigabatrin Stories

2010-10-21 13:43:48

A dozen new epilepsy drugs are giving doctors and patients more options, but making treatment decisions more complex, a Loyola epilepsy specialist reports in the journal Neurologic Clinics. "Clinicians practice in an era of abundance of anti-epileptic drugs," Dr. Jorge J. Asconap© wrote. The new drugs provide "an opportunity to better meet the needs of more patients." Asconap©'s article will appear in the November issue of Neurologic Clinics, now available online. Since 1993, the...

2010-07-27 13:00:22

While the Food and Drug Administration (FDA) requires a warning of an increased risk of suicide for all epilepsy drugs, a new study shows that only certain drugs may increase the risk. The study is published in the July 27, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology. Newer drugs with a higher risk of causing depression than other epilepsy drugs, such as levetiracetam, topiramate and vigabatrin, were found to increase the risk of...

2010-06-09 07:03:00

CORAL GABLES, Fla., June 9 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on Tuesday, June 15th at 5:20pm local time, Charles Gorodetzky, MD, PhD will deliver a presentation entitled "Vigabatrin for the treatment of stimulant dependence" at the College on Problems of Drug Dependence's (CPDD) 72nd Annual Meeting in Scottsdale, Arizona. Dr. Gorodetzky, Catalyst's Chief Medical Officer, will present an overview of nonclinical and clinical...

2010-05-18 07:03:00

CORAL GABLES, Fla., May 18 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced its financial results for the three month period ended March 31, 2010. The Company reported a net loss of $1,045,043, or $0.06 per basic and diluted share, compared to a net loss of $3,031,201, or $0.22 per basic and diluted share, for the same period in 2009. Research and development expenses for the first quarter of 2010 were $439,587, compared to $2,460,632 in the...

2010-05-07 07:03:00

CORAL GABLES, Fla., May 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that Jack Weinstein, Catalyst's Chief Financial Officer, will be making a presentation at the MoneyShow Conference to be held May 10th through May 13th at Caesars Palace in Las Vegas. Catalyst will present a Corporate Overview, including its development plans for CPP-109 and CPP-115. Further, the Company reported that its presentation materials from the conference will be...

2010-04-26 10:10:00

CORAL GABLES, Fla., April 26 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it has received notice from The NASDAQ Stock Market ("NASDAQ") confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. As previously announced, on November 13, 2009 NASDAQ notified the Company that the bid price of its common stock had closed at less than $1.00 per...

2010-04-13 09:49:00

CORAL GABLES, Fla., April 13 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies...

2010-04-09 07:03:00

CORAL GABLES, Fla., April 9, 2010 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: "A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of...

2010-04-01 07:03:00

CORAL GABLES, Fla., April 1 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009. "In 2009, we transformed Catalyst into a multi-product company with compounds that have potential to address a variety of diseases...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related